Opdivo did well in less then twenty percent of patients ie "responders" pd1 positive patients 20 months. Bavituximab will make all patients responders . I believe we see complete responses in the durvolumab trial when combined with Bavituximab . Cancer will be seen as a chronic disease not a death sentence .
Market Data 
Markets 
AI
